Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring adenocarcinoma of the prostate, stage I prostate cancer, stage II prostate cancer, stage III prostate cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed adenocarcinoma of the prostate Stage I-III disease (T1-T3, N0, M0) No clinical or radiographic evidence of metastasis If prostate-specific antigen (PSA) ≥ 10.0 ng/mL and Gleason score is 7, a radioisotope bone scan must show no evidence of metastasis No evidence of lymphatic or visceral metastases of the abdomen or pelvis on CT scan or MRI PSA ≤ 20 ng/mL Gleason score ≤ 7 (if stage T3 , score must be < 7) PATIENT CHARACTERISTICS: Performance status Not specified Life expectancy More than 10 years Hematopoietic Not specified Hepatic Not specified Renal Not specified Other No other malignancy within the past 5 years except basal cell or squamous cell skin cancer PRIOR CONCURRENT THERAPY: Endocrine therapy Prior hormonal therapy allowed provided it was initiated no more than 2 months ago, and may include the following: Luteinizing hormone-releasing hormone agonists (e.g., goserelin, leuprolide) Anti-androgens (e.g., flutamide, bicalutamide) Radiotherapy No prior pelvic irradiation Surgery No prior radical prostatectomy